Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2026-08-20 16:01:28 ET · period of report 2026-08-18 · accession 0001697422-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-20 16:01 | 2026-08-18 | REGN | Fenimore Christopher R. | EVP Fin CFO | M - OptEx | $381.92 | +6,283 | 24.6K | +34% | +$2.40M |
| D | 2026-08-20 16:01 | 2026-08-18 | REGN | Fenimore Christopher R. | EVP Fin CFO | F - Tax | $813.47 | -4,599 | 20.0K | -19% | -$3.74M |
| D | 2026-08-20 16:01 | 2026-08-18 | REGN | Fenimore Christopher R. | EVP Fin CFO | M - OptEx | $0.00 | -6,283 | 6,000 | -51% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-18 | M | A | 6,283 | $381.92 | 24,583 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-18 | F | D | 4,599 | $813.47 | 19,984 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-08-18 | M | D | 6,283 | $0.00 | 6,000 | D | $381.92 · — to 2026-12-16 | 6,283 Common Stock | (F2) The stock option award vested in four equal annual installments, commencing one year after the date of grant. |